Cloudbreak Pharma Inc. (“Cloudbreak Pharma”) has strengthened its board oversight by appointing Mr. Chan Sheung Yan Andrew and Mr. Kwai Sze Kit as independent non-executive directors (INEDs), effective 23 September 2026.

The pair will serve initial three-year terms under identical letters of appointment that provide annual remuneration of US$0.02 million each, subject to annual review by the Board’s Remuneration Committee. Either party may terminate the engagement with at least 30 days’ written notice.

Profile of the new INEDs • Mr. Chan, aged 46, is currently Chief Executive Officer of ZMF Asset Management Ltd. and brings over 20 years of investment-banking and capital-markets experience. He holds an economics degree from National Tsing Hua University and is a licensed responsible officer for Type 1, 4 and 9 regulated activities under Hong Kong’s Securities and Futures Commission. • Mr. Kwai, aged 51, is Director of Legal and Compliance at Harbour Equine Holdings Ltd. and has more than two decades of legal, compliance and regulatory experience, including roles at Credit Suisse, ICBC (Asia) and Ping An of China Securities. He holds law degrees from the City University of Hong Kong and The University of Hong Kong and was admitted as a Hong Kong solicitor in 2012.

Both appointees meet the independence criteria under Listing Rule 3.13, hold no shares in Cloudbreak Pharma or its affiliates, and have no relationships with substantial or controlling shareholders.

Independent Special Committee In light of concerns raised by the Securities and Futures Commission regarding alleged manipulation of Cloudbreak Pharma’s initial public offering, the Board intends to establish an Independent Special Committee comprised solely of INEDs to supervise an internal investigation. Progress updates and findings will be disclosed in due course.

Trading Suspension Cloudbreak Pharma shares have been suspended from trading on the Hong Kong Stock Exchange since 09:00 a.m. on 10 September 2026, following regulatory directives, and will remain suspended until further notice. Investors are advised to exercise caution when dealing in the company’s securities.

Board Composition Following the appointments, Cloudbreak Pharma’s Board now consists of five INEDs, three executive directors and three non-executive directors. Dr. Ni Jinsong continues as Chairman, Executive Director and Chief Executive Officer.